China Resources Pharmaceutical Group Past Earnings Performance
Past criteria checks 4/6
China Resources Pharmaceutical Group has been growing earnings at an average annual rate of 2.4%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 8.1% per year. China Resources Pharmaceutical Group's return on equity is 8.4%, and it has net margins of 1.6%.
Key information
2.4%
Earnings growth rate
2.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 8.1% |
| Return on equity | 8.4% |
| Net Margin | 1.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow China Resources Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 244,704 | 3,854 | 25,252 | 0 |
| 30 Jun 23 | 247,532 | 3,852 | 25,157 | 0 |
| 31 Mar 23 | 228,091 | 3,634 | 23,057 | 0 |
| 31 Dec 22 | 224,528 | 3,665 | 22,569 | 0 |
| 30 Sep 22 | 227,563 | 3,854 | 22,823 | 0 |
| 30 Jun 22 | 211,788 | 3,719 | 21,193 | 0 |
| 31 Mar 22 | 196,226 | 3,288 | 19,674 | 0 |
| 31 Dec 21 | 193,021 | 3,072 | 19,393 | 0 |
| 30 Sep 21 | 191,495 | 2,869 | 19,667 | 0 |
| 30 Jun 21 | 187,554 | 2,626 | 19,701 | 0 |
| 31 Mar 21 | 179,512 | 2,720 | 19,092 | 0 |
| 31 Dec 20 | 168,762 | 2,776 | 18,197 | 0 |
| 30 Sep 20 | 171,873 | 2,683 | 19,137 | 0 |
| 30 Jun 20 | 174,956 | 2,578 | 20,122 | 0 |
| 31 Mar 20 | 181,054 | 2,793 | 21,233 | 0 |
| 31 Dec 19 | 182,690 | 2,937 | 21,813 | 0 |
| 30 Sep 19 | 183,417 | 3,670 | 21,984 | 0 |
| 30 Jun 19 | 173,938 | 4,187 | 20,930 | 0 |
| 31 Mar 19 | 165,679 | 3,737 | 20,069 | 0 |
| 31 Dec 18 | 166,626 | 3,494 | 20,322 | 0 |
| 30 Sep 18 | 163,734 | 3,466 | 19,540 | 0 |
| 30 Jun 18 | 154,852 | 3,309 | 18,062 | 0 |
| 31 Mar 18 | 142,296 | 2,959 | 15,795 | 0 |
| 31 Dec 17 | 143,688 | 2,901 | 15,087 | 0 |
| 30 Sep 17 | 143,252 | 2,759 | 14,277 | 0 |
| 30 Jun 17 | 142,276 | 2,602 | 13,380 | 0 |
| 31 Mar 17 | 142,003 | 2,577 | 13,395 | 0 |
| 31 Dec 16 | 140,316 | 2,526 | 13,279 | 0 |
| 30 Sep 16 | 132,253 | 2,161 | 12,534 | 0 |
| 30 Jun 16 | 129,313 | 1,889 | 12,274 | 0 |
| 31 Mar 16 | 123,770 | 2,103 | 11,766 | 0 |
| 31 Dec 15 | 122,785 | 2,388 | 11,692 | 0 |
| 31 Dec 14 | 108,575 | 2,116 | 9,955 | 0 |
| 31 Dec 13 | 91,313 | 2,061 | 9,248 | 0 |
Quality Earnings: 3320 has high quality earnings.
Growing Profit Margin: 3320's current net profit margins (1.6%) are lower than last year (1.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3320's earnings have grown by 2.4% per year over the past 5 years.
Accelerating Growth: 3320's earnings growth over the past year (5.2%) exceeds its 5-year average (2.4% per year).
Earnings vs Industry: 3320 earnings growth over the past year (5.2%) exceeded the Pharmaceuticals industry 1.3%.
Return on Equity
High ROE: 3320's Return on Equity (8.4%) is considered low.